NBTXR3, a radiation enhancer for in situ cancer vaccine

2016, Paris S. et al.

Authors

Paris S.1, Pottier A.1, Levy L.1, Lu B.2
1 – Nanobiotix, Paris, France
2 – Thomas Jefferson University

Summary

NBTXR3 exposed to irradiation enhanced cancer cells destruction and immunogenic cell death compared to irradiation alone, suggesting a strong potential for transforming tumor into an effective in situ vaccine. This may contribute to transform “cold” tumor into “hot” tumor and effectively be combined with most of the immunotherapeutic agents across oncology.

Read Article

Contact

For more information contact our Medical affairs team at medicalaffairs@nanobiotix.com